The HUS Comprehensive Cancer Center is Finland’s largest cancer research center. We are investigating new cancer treatments that are often not yet publicly available. A new cancer drug that does not yet have marketing authorization is the subject in many research projects. The Comprehensive Cancer Center has more than 100 ongoing trials each year.
Becoming a research patient in a pharmaceutical trial
You can apply to become a research patient in clinical cancer research by referral from a physician. If necessary, you can also directly contact the Clinical Trial Unit for more information on ongoing cancer research.
Suitability for research
In order to participate in a cancer study as a research patient, you must meet the eligibility requirements for the study. The requirements vary from study to study and are defined in detail in each research plan. Please follow the instructions you have received from your research physician or research nurse.
If, after you have contacted us, it appears that you may be suitable for an ongoing study at the Comprehensive Cancer Center, we will ask you to sign the research patient bulletin and the consent document for the relevant study.
We will then carry out more detailed evaluation of your eligibility for the treatment study. This evaluation usually includes laboratory tests and X-ray examinations. Both testing for eligibility and participation in the clinical trial are free of charge for you. You can participate in Comprehensive Cancer Center studies regardless of your municipality of residence.
Taking part in a clinical study is always voluntary. You can withdraw your consent to participate in the study at any time without involving any negative consequences for you as the subject.
Research activities approved by the authorities
All clinical trials carried out at the Comprehensive Cancer Center have been approved by the Ethics Committee. Clinical trials are also approved by the Finnish Medicines Agency (FIMEA).
Cooperation with us
We cooperate with the pharmaceutical industry and product development. You can contact us and suggest a research topic!
The Comprehensive Cancer Center has currently approximately 150 ongoing studies, of which drug trials are a significant part. In all our research activities, we adhere to the best ethical principles. We carry out the studies in accordance with good clinical practice, considering the interests of the research patient a priority. In our research activities, we also follow the Declaration of Helsinki.
New studies can be offered to the Comprehensive Cancer Center by sending a message to email@example.com@teskumiktutapoysteduu , or directly to the researcher.
Obtaining a hospital research permit for a pharmaceutical trial requires the approval of the Ethics Committee and FIMEA, as well as a financial agreement. The total duration of the permit processing from the research offer to its approval is approximately two months. Permits and agreements can be prepared and processed simultaneously.
Permit and agreement schedules:
- The processing of the HUS research permit takes about a week.
- The Ethics Committees meets every week to process requests for an opinion. The request for an opinion must be submitted two weeks before the committee meeting.
- FIMEA shall deliver its opinion within two months of the date when notification on the study was provided.
- Clinical Research Institute HUCH is responsible for preparing the economic agreement.